Actovegin application in treatment of diabetic polyneuropathy and preventive maintenance of diabetic foot syndrome in surgical patients with type 2 diabetes mellitus and arterial hypertension


Cite item

Full Text

Abstract

On the basis of the Voronezh municipal hospital of the first help №10 in type 2 diabetes mellitus patients with diabetic polyneuropathy and arterial hypertension total oxidative capacity increase, LDLс oxidized antibodies enhanced level and total antioxidative capacity deficiency were revealed. Antioxidative and antihypoxemic action caused by actovegin in 400 mg daily dose in diabetic patients are established. We observed that actovegin indication produces corrective influence
on lipid peroxidation parameters and promotes improvement of diabetic polyneuropathy clinical implications preventive maintenance of diabetic foot syndrome.

About the authors

Voronezh state medical Academy named. N. N. Burdenko

Author for correspondence.
Email: author@vestnik-surgery.com
assistant of endocrinology Department, Voronezh state medical Academy named. N. N. Burdenko Russian Federation

Voronezh state medical Academy named. N. N. Burdenko

Email: author@vestnik-surgery.com
doctor of medical Sciences, Professor, head of the endocrinology Department of the Voronezh state medical Academy named. N. N. Burdenko Russian Federation

Voronezh state medical Academy named. N. N. Burdenko

Email: author@vestnik-surgery.com
PhD, assistant of endocrinology Department, Voronezh state medical Academy named. N. N. Burdenko Russian Federation

References

  1. Dedov I. I., Udovichenko O. V.,[ Galstyan G.R. Stop Diabetic. ]M.: Practical medicine, 2005; 197.
  2. Dedov I. I., Shestakova M.In. [Algorithms of specialized medical care for patients with diabetes. ]– M.: Media sphere, 2009; 103.
  3. In Kreminskaya.M. Gurieva I. V.[ the Possibility of using Actovegin in case of late complications of diabetes. Russian medical journal.] 2004; 12: 9: 564-567.
  4. F Morgoeva.E., Ametov A. S., [Strokov.And. Encephalopathy and Diabetic polyneuropathy: therapeutic possibilities Actovegin. Russian medical journal]. 2005; 13: 6: 302-304.
  5. In Obolensky.N. [Complex treatment of patients with diabetic foot syndrome. Farmateka ]2008; 8: 49-52.
  6. [Clinical experience of Actovegin in endocrinology. ]– M.: RCT Sovero press, 2005; 72.
  7. Sych, Y. P., Zilov A.V. [Actovegin: treatment and prevention of diabetes complications. Physician ] 2005; 3: 56-59.
  8. Apelqvist J., Bakker K., Van Houtum W. H., Schaper N. C. [practical guidelines on the management and prevention of the diabetic foot: International consensus on the diabetic foot ](2007). Diabetes Metab RES REV 2008; 24: 1: 181-187.
  9. D. Bouhassira, N. Attal, H. Alchaar et al.[ Comparison of pain syndromes associated with nervous or somatic lesions and development of a new diagnostic questionnaire for neuropathic pain ]DN4. Pain 2005; 114: 1-2: 29-36.
  10. Cameron N. E., Cotter M. A.[ Pro-inflammatory mechanisms in diabetic nephropathy: focus on nuclear factor Kappa B path. Curr Drug Targets ]2008; 9: 1: 60-67.
  11. A. Veves, R. A. Malik,[ diabetic Neuropathy: clinical management of the GP. Humana Press], 2007; 516.
  12. Dordević G., S. Durić, Apostolskit S. et al. [The total antioxidant capacity of blood in patients with diabetes mellitus type 2 with distal symmetrical polyneuropathy. Vojnosanit Pregl ]2008; 65: 9: 663-669.
  13. Dick P. J. [Detection, characterization and staging of polyneuropathy: assessed in diabetes mellitus patients. Muscle Nerve ]1988; 11: 1: 21-32.
  14. Jacob S., Dietze G. J., Machicao, F. et al.[ Improvement of glucose metabolism in patients with type II diabetes after treatment with hemodialysate. Arzneimittelforschung] 1996; 46: 269-272.
  15. Kaya A., I. Uzunhasan, M. [Baskurt Oxidative status and lipid profile in metabolic syndrome: gender differences. Metab Syndr Relat To Use Others,] 2010; 8: 1: 53-58.
  16. Munich-Kusser B., S. Muhlbacher, Mushack J. et al.[ Further evidence for a two-step model of glucose-transport regulation. The Inositol phosphate oligosaccharides regulate glucose-carrier activity.] Biochem J. 1989; 261: 699-705.
  17. Pop-Busui, R., SIMA A., Stevens M. [diabetic neuropathy and oxidative stress. Diabetes Metab RES Rev.] 2006; 22: 4: 257-273.
  18. Classification Thomas K. P., [differential diagnosis and staging of diabetic peripheral neuropathy ] P. K. Thomas. Diabetes 1997; 46: 2: S54-S57 Standard.
  19. [Patients with diabetes ] Ziegler D., Movsesyan L., Mankovsky B. [treatment of symptomatic polyneuropathy With Actovegin In type. Diabetes Care ]2009; 32: 8: 1479-1484.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2010 ., ., .

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies